Akeso, Inc. (HKG:9926)
Hong Kong
· Delayed Price · Currency is HKD 82.95
-0.75 (-0.90%)
Apr 17, 2025, 4:08 PM HKT
Akeso Revenue
In the year 2024, Akeso had annual revenue of 2.12B CNY, down -53.08%. Akeso had revenue of 1.10B in the half year ending December 31, 2024, with 62.96% growth.
Revenue
2.12B CNY
Revenue Growth
-53.08%
P/S Ratio
32.94
Revenue / Employee
699.82K CNY
Employees
3,035
Market Cap
74.45B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| Sino Biopharmaceutical | 30.72B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Akeso News
- 7 days ago - Why This Chinese Biotech Could Be Pharma's DeepSeek - Benzinga
- 18 days ago - Akeso reports FY results - Seeking Alpha
- 4 weeks ago - Chinese drug maker Akeso hailed as biotech's 'DeepSeek moment' amid US competition - Yahoo
- 4 weeks ago - Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US competition - South China Morning Post
- 5 months ago - BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga
- 5 months ago - Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Benzinga